For immunohistochemical demonstration of the enkephalin octapeptide Met5-enkephalin-Arg6-Gly7-Leu*, the peptide was conjugated with a carrier protein using either glutaraldehyde or 1-ethyl-3 (3&ethylaminopropyl)-carbodiimide as coupling agent. Antisera were raised in rabbits and their specificity was studied using the immunoblotting technique. The results suggest that glutaraldehyde selectively couples the amino terminus of the peptide to the carrier protein, while carbodiimide coupling produces a mixture of specificities. Accordingly, antiserum raised against the glutaraldehde-indud conjugate specitically recognized the peptide carboxyl terminus and allowed immunohistochemical distinction of the octapeptide from other closely related opioid peptides, such as Leu5-and Met5-enkephalin, Met5-
Introduction
Two opioid pentapeptides, methionine5-(met-) and leucine5-(leu-) enkephalin, were first isolated from the brain and have since been detected in several neuron systems of both the central and peripheral nervous systems (15). Subsequent research has revealed the presence of several other opioid peptides that are chemically closely related to the two pentapeptides (19). These peptides are collectively referred to as enkephalins and are derived from three different precursor molecules, pro-enkephalin A and B and proopiomelanocortin (38) .
Opioid peptides have been detected in both the central and peripheral nervous systems of vertebrates (9, 31, 32, 39, 42, 43) . Evidence for opioid peptides has also been found in invertebrate species (22,24), raising the possibility that the neurointegrative action of these peptides may be addressable using small sets of identifiable neurons. Given the wide distribution of structurally closely related molecules in different animal groups and their potential importance in neurobehavioral responses, it has become essential 40:231-239, 1992) to examine the methodology required to identlfy their specific localization in neural tissues.
Being relatively small molecules, the opioid peptides themselves are not immunogenic. Therefore, their immunohistochemical demonstration is based on antibodies raised against opioid peptide-protein conjugates. Considering the close structural relationship between various opioid peptides (Figure l) , it is evident that immunohistochemical differentiation of a particular peptide from other opioid peptides depends on which end of the molecule the antibodies recognize. One aim of the present study was to examine how the reaction conditions affect coupling of enkephalins to the carrier protein. We were particularly interested in the opioid octapeptide methionine5-enkephalin-arginine6-glycine7-leucine8 (MEAGL), which is a specific marker for pro-enkephalin A (7, 11, 27, 28) .
Immunohistochemical localization of small molecular weight antigens is based on the assumption that fixation immobilizes the substance studied by inducing a coupling reaction with tissue proteins. The resulting complex should be identical or closely similar to that used for antibody production. This problem has been addressed previously in connection with several neuroactive substances other than enkephalins (35) (36) (37) . The present study examines how addition of the coupling agent to the fixative affects visualization of MEAGL in tissue sections. 
Materials and Methods

Preparation of Conjugates ana' Raising of Antisera
Conjugation of MEAGL, the opioid heptapeptide methionine'-enkephalinarginine'-phenylalanine' (MEAP), met-enkephalin, leu-enkephalin, or Phe-Met-Arg-Phe-amide (FMRFamide) to a highly immunogenic carrier protein, Limulus hemocyanin (HC), was performed using either l-ethyl-3(3-dimethylaminopropy1)-carbodiimide or glutaraldehyde as a coupling agent.
No attempt was made to determine the molar coupling ratio, since the reported range of such ratios is wide and no linear relationship between coupling ration and antigenicity seems to exist (23). Glutaraldehyde was obtained from Kodak (Rochester, NY); all other chemicals were from Sigma (St Louis, MO).
Glutaraldehyde-induced Conjugation. Five mg ofpeptide were dissolved in 5 ml of either 0.1 M sodium phosphate buffer, pH 7.4, 0.2 M sodium acetate, pH 5.5, or 0.1 M sodium borate, pH 9.0. Four ml of this solution were mixed with 2.5 ml HC (2 mg/ml in water). Four hundred p1 glutaraldehyde ( 5 % solution in buffer) were added dropwise and incubation was allowed to proceed for 15 min at room temperature. The reaction mixture was dialyzed against distilled water at 4°C ( 5 x 8 liters) for 3 days. Protein content was determined photometrically using a modified Lowry method and the conjugates were stored at -20'C.
One-step Carbodiimide Conjugation. Two hundred mg glutaric anhydride and 100 mg HC were dissolved in 20 ml 0.1 M Na-borate buffer, pH 9.0. The reaction was allowed to proceed for 1 hr at room temperature under constant mixing and the mixture was dialyzed against distilled water for 3 days. Five mg peptide were dissolved in 5 m10.2 M Tris-HCI buffer, pH 8.0. This was mixed with 1 ml glutaraldehyde-treated HC solution (2.9 mglml in water; see above). Four ml carbodiimide (2.5 mg/ml in buffer, pH 8.0) were added dropwise under constant stirring and the reaction was allowed to proceed overnight at room temperature. The reaction mixture was dialyzed against distilled water at 4'C for 3 days. Protein content was measured as above, and the conjugates were stored at -2 O C Two-step Carbodiimide Conjugation. One hundred pl carbodiimide (10 mglml) and 1 ml glutaraldehyde-treated HC (0.24 mglml), both in 0.01 M sodium phosphate buffer, pH 5.0, were mixed and incubated at room temperature for 2 min. One ml MEAGL (0.87 mglml) or metenkephalin (0.87 mglml) in 0.2 M sodium phosphate buffer, pH 8.0, was added and the reaction was allowed to proceed overnight at room temperature. The mixcure was dialyzed against 0.1 M sodium phosphate, pH 8.0, and then against water for 3 days. tion and the serum was separated, aliquotted, and stored at -20'C. The antiserum raised against glutaraldehyde-induced MEAGLHC conjugate is referred to as antiserum 935, and that raised against carbodiimide-induced MEAGLHC conjugate as antiserum 934.
For some experiments, commercially available met-enkephalin and FMRFamide antisera, raised against glutaraldehyde-induced peptide-protein conjugates (Incstar; Stillwater, MN), were used.
Immunohistochemistry
Adult male Sprague-Dawley rats (200 g) and Swiss-Webster mice (50 g) were anesthetized with sodium pentobarbital and perfused transcardially with one of the following fixatives: 4% formaldehyde in 0.1 M sodium phosphate buffer, pH 7.4; 4% glutaraldehyde in 0.1 M sodium phosphate buffer, pH 7.4; 4% formaldehyde and 0.1% glutaraldehyde in 0.1 M sodium phosphate buffer, pH 7.4; or 4% carbodiimide in 0.1 M sodium phosphate buffer, pH 7.4. The superior cervical ganglia, the major pelvic ganglia, the thoracic segment of the spinal cord, and the pituitary gland were dissected out, rinsed extensively in the buffer, and transferred into PBS, pH 7.6, containing 20% sucrose. Cryostat sections 16 pm thick were cut on chromalum-gelatin-coated glass slides and rehydrated in PBS (pH 7.6) containing 0.25% Triton X-100 (PBS-Triton). The slides were incubated with 10% normal swine serum for 15 min and with rabbit anti-MEAGL diluted 1:lOOO in PBS-Triton overnight at 4'C. After rinsing with PBS-Triton. the specimens were incubated with swine anti-rabbit IgG conjugated with tetramethylrhodamine isothiocyanate (Dako R156: Dako, Santa Barbara, CA) diluted 1:lOO inJBS-Triton for 60 min at room temperature. After rinsing in PBS, the specimens were mounted in PBS-glycerol (50l50) and examined using a ztiss Universal microscope equipped with a mercury lamp and Zeiss filter block 487712 (excitation maximum 546 nm, emission barrier >590 nm).
To control for nonspecific fluorescence, consecutive sections of each tissue were stained with MEAGL antiserum, non-immune serum, or antiserum raised against glutaraldehyde-treated carrier protein, all ai the same dilution. To compare the effects of different fiitives on nonspecific fluorescence, the corresponding tissue blocks from separate, perfusion-fmd animals were treated identically with either MEAGL antiserum or non-immune serum.
Specificity ana' Sensitivity Tests
Immunoblotting. Tenfold dilution series (10 pg/ml-lO nglml) of conjugates were prepared and 1-pl aliquots of conjugate were pipetted onto nitrocellulose (Sigma; pore size 0.45 pm). The nitrocellulose slips were airdried for 30 min, wetted with washing buffer containing 0.15 M NaCI, 0.01 M Trizma base, 0.01 M Trizma-HC1, pH 7.6, and incubated with non-fat milk powder (0.5% solution in the washing buffer) at 40'C for 1 hr to block remaining nonspecific protein binding capacity. The slips were incubated with primary antibody diluted 1:lOOO. then with swine anti-rabbit IgG (DAKO 2196) diluted 1:100, with rabbit peroxidase-anti-peroxidase (PAP) complex (DAKO 2113) diluted 1:lOO. and with a developing mixture containing 3 ml washing buffer, 180 ~1 3 % alpha-chloronaphthol, and 12 pl 30% H202. All incubations, except for blocking, were performed at room temperature: incubation time was 60 min for the primary and secondary antibodies and for PAP, and 15 min for the developer. Between incuba-Immunization. One halfml of glutaraldehyde-or carbodiimide-induced MEAGLHC conjugate solution (2 mg/ml) was emulsified with 0.5 ml of Freund's complete adjuvant and injected subcutaneously into five sites (0.2 mllsite) in the back of a female New Zealand Black rabbit. Booster injections were given 4 and 7 weeks after the primary immunization and consisted of 0.5 ml conjugate and 0.5 ml Freund's incomplete adjuvant, SC, 0.2 mllsite on five sites. The rabbits were bled 10 days after the last injec-tions the immunoblots were rinsed five times with the washing buffer.
To determine the amount of HC needed for absorption of the immunoglobulins specific for the carrier protein, 1-p1 aliquots containing 10, 1, or 0.1 p g / d HC were pipetted onto nitrocellulose and tested against MEAGL antisera diluted 1:lOOo and pre-absorbed with 100, 10, or 1 &ml solutions of HC. The results indicated that pre-absorption with 0.1 mg/ml glutaraldehyde-treated HC is required to block the HC-specific antibodies completely in 1:1oOO dilution ofthe antisera. Therefore. to study the MEAGL specific antibodies separately from those directed to the carrier protein. the antisera were routinely pre-absorbed with 1 mg/ml HC. In specificity experiments the primary antiserum was preabsorbed with 10 pglml or 100 pg/ml solution of met-enkephalin-HC, leu-enkephalin-HC. MEAGLHC.
MEAP-HC, or FMRFamidc-HC.
Absorption Expcrhcnts on Tissue Sections. Consecutive sections through rat spinal cord. sympathetic ganglia, or pituitary gland were cut on scparate glass slides and incubated either with non-immune rabbit serum, antiserum 935 or 934, or the same antisera pre-absorbed with 10 pg/ml and 100 pglml solutions of met-enkephalin-HC, leu-enkephalin-HC, MEAGL HC. MEAP-HC, or FMRFamidc-HC or HC. The sections were processed as described above.
Results
Immunoblotting of Glutaraldehyde-induced Conjugates
The antiserum raised against glutaraldehyde-induced MEAGLHC conjugate is referred to as antiserum 935. Figure 2A shows immunoreactivity of antiserum 935 for MEAGLprotein conjugate and several closely related opioid peptide-protein conjugates, which were prepared under identical conditions. Antiserum 935 detected the MEAGL conjugate but failed to detect the corresponding MEAP, met-enkephalin, leu-enkephalin, and Fh4RFamide conjugates. Identical blots were incubated with anti-met-enkephalin and anti-FMRFamide antisera to control that conjugation of the corre- sponding peptides to H C had actually occurred (Figures 2B and C) . Non-reactivity of dots containing only the carrier protein indicates that the antibodies directed to the carrier protein have been removed by the pre-absorption; hence, all reactivity observed is due to epitopes containing the opioid peptide. These observations suggest that antiserum 935 recognizes specifically the MEAGL carboxyl terminus, which distinguishes it from the other peptides, while it fails to recognize the amino terminus, which is common for metand leu-enkephalin, MEAP. and MEAGL (Figure 1) .
Anusenun 935 detected 1 ng of MEAGLHCconjugate but failed to detect up to 1 pg of the other conjugates, indicating that if there is any crossreactivity between these substances the corresponding crossreactivity ratios are less than 1:10,000. High specificitywas also confirmed by pre-absorption experiments in which incubation of the antiserum 935 with 10 pglml MEAGLHC before immunoblotting abolished the reactivity completely, whereas incubation with met-enkephalin-HC or leu-enkephalin-HC in 100 pglml concentration did not affect the intensity of MEAGL immunoreactivity at all (data not shown). Met-enkephalin antiserum, which was raised against glutaraldehyde-induced met-enkephalin-HC, recognized glutaraldehydeinduced MEAGL, MEAP, met-and leu-enkephalin conjugates but failed to recognize glutaraldehyde-induced FMRFamide conjugate ( Figure 2B ). FMRFamide antiserum detected glutaraldehydeinduced MEAP and FMRFamide conjugates ( Figure 2C ).
Immunoblotting of Carbodiimide-induced Conjugates
The antiserum raised against carbodiimide-induced MEAGLHC conjugate is referred to as antiserum 934. Unless otherwise stated, the one-step carbodiimide conjugation procedure was used through-out this study. Figure 2D shows immunoreactivity of antiserum 934 to carbodiimide-induced MEAGLHC, met-enkephalin-HC, and leu-enkephalin-HC conjugates prepared under identical conditions. Antiserum 934, pre-absorbed with the carrier protein, detected all three conjugates with approximately equal sensitivity. This suggests that antiserum 934 recognizes the MEAGL amino terminus, which is identical with those of met-and leu-enkephalin. This was confirmed by a pre-absorption experiment in which incubation with 1 Clglml of any of the three conjugates abolished MEAGL immunoreactivity completely (data not shown). By contrast, the met-enkephalin antiserum, raised against glutaraldehyde-induced conjugate, showed barely detectable immunoreactivity for carbodiimideinduced MEAGL, met-enkephalin, and leu-enkephalin conjugates (Figure 2E ).
To examine whether antiserum 934 would be specific for the MEAGL amino terminus, it was tested against the glutaraldehydeinduced met-enkephalin, leu-enkephalin, and MEAGL conjugates. Antiserum 934 recognized glutaraldehyde-induced MEAGL conjugates but failed to recognize corresponding met-and leuenkephalin conjugates, suggesting that some of its antibodies are directed against the MEAGL carboxyl terminus ( Figure 2F ), and therefore this antiserum contains antibodies specific for both MEAGL amino and carboxyl termini.
To obtain better control over carbodiimide-induced conjugation, a two-step reaction was introduced (8) in which the component with carboxyl group desired for conjugation was first incubated with carbodiimide at acidic pH, and the component with the desired amino group was added at alkaline pH. Met-enkephalin and MEAGL conjugates produced using this procedure were recognized by antiserum 934, antiserum 935, and anti-met-enkephalin antiserum, suggestion that the conjugates resulting from the two-step reaction contain a mixture of specificities (data not shown).
Effect of )H on Conjugation Reactions
Since ionization of the carrier protein and MEAGL, as well as the reactions of glutaraldehyde, depends on pH, it was of interest to examine whether a change in pH affects conjugation of MEAGL and met-enkephalin to protein per se, or the specificity of the conjugates. Figures 3A and 3B show the immunoreactivity of antiserum 935 and met-enkephalin antiserum, respectively, for glutaraldehydeinduced MEAGLHC and met-enkephalin-HC conjugates prepared at pH 7.4, 5.5, and 9.0. Antiserum 935 recognized the MEAGLHC conjugates prepared at pH 7.4 and 9.0, although its sensitivity for the alkaline conjugate was slightly reduced. Met-enkephalin antiserum, which readily detected both MEAGL and met-enkephalin conjugates raised at pH 7.4, showed only weak reactivity for the conjugates prepared at pH 9.0. In contrast, neither antisera, or antiserum 934, showed immunoreactivity for the glutaraldehydeinduced conjugates raised at pH 5.5. Figures 3C and 3D show immunoreactivity of the antiserum 934 and met-enkephalin antiserum, respectively, for carbodiimideinduced MEAGLHC and met-enkephalin conjugates prepared at pH 8.0 or pH 5.5. Antiserum 934 clearly detected all conjugates, whereas met-enkephalin antiserum showed only barely visible reactivity, there being no essential differences due to pH.
Effect of Tissue Fixative on MEAGL Immunoreactivity
Immunoblotting was used to examine whether fixation per se affects antigenicity of the peptide-protein conjugates. Nitrocellulose slips containing a series of 100-ng to 10-pg dots of each opioid peptide-protein conjugate were incubated for 2 hr with 4% formaldehyde, 4% formaldehyde + 0.1% glutaraldehyde, or 4% carbodiimide. None of the fixatives significantly reduced the immunoreactivity of the conjugates (data not shown).
Immunohistochemistry
Three rat tissues-the spinal cord, the sympathetic ganglia, and the pituitary gland, in which the presence of MEAGL has been demonstrated by immunohistochemical and biochemical methods (13,16,30)-were used to study whether inclusion of the coupling agent in the fixative improved preservation of MEAGL immunoreactivity in tissue. Preliminary studies indicated that glutaraldehyde alone, although it results in excellent tissue preservation, causes unacceptable background fluorescence even as a 0.1% solution. However, when 0.1% glutaraldehyde was combined with 4% formaldehyde no significant increase in background fluorescence was observed in any of the tissues studied, as revealed by comparison of sections incubated with non-immune serum. Therefore, immunoreactivity to antiserum 935 in formaldehyde-fixed tissue was compared with that in formaldehyde-glutaraldehyde-fixed tissue. Previous studies indicate that carbodiimide alone can be used successfully as tissue fixative for immunohistochemistry (17.30). Therefore, immunoreactivity to antiserum 934 in formaldehyde-fixed tissue was compared with that in carbodiimide-fixed tissue.
Antiserum 935. In the thoracic spinal cord of formaldehydefixed animals, MEAGLimmunoreactive varicose fibers were seen both in the ventral and dorsal horns, their density being greatest in Laminae I and I1 ( Figure 4A ). A plexus of immunoreactive fibers was also seen in the lateral funiculus of the white matter, immediately lateral to the dorsal horn. Some dorsal horn neurons showed slight staining ( Figure 4A ). In animals fixed with glutaraldehyde-formaldehyde, the density of MEAGLimmunoreactive fibers seemed greater than in formaldehyde-fixed tissue (Figures 4A and 4B) . Several intensely immunoreactive neurons were found in several laminae of the dorsal horn ( Figure 4B) , whereas no such cells were seen in formaldehyde-fixed tissue ( Figure 4A ). In the superior cervical ganglion and the major pelvic ganglion, a few weakly stained neurons and intensely stained varicose fibers around several neurons were observed in formaldehyde-fixed animals (not shown). By visual examination, there was no essential enhancement in neuronal staining between formaldehyde and formaldehydeglutaraldehyde fixation. However, the latter fixative seemed to preserve more basket-like MEAGLimmunoreactive fiber formations around neurons. In the pituitary gland of formaldehyde-fixed animals, MEAGLimmunoreactive cells were occasionally seen in the anterior lobe and some MEAGLimmunoreactive varicose fibers were seen in the peripheral parts of the posterior lobe, whereas the intermediate lobe was completely devoid of MEAGL immunoreactivity ( Figure 5A ). Formaldehyde-glutaraldehyde fixation resulted in a similar staining pattern in the anterior lobe. In addition, it Figure 5B ). The antiserum raised against glutaraldehyde-treated carrier protein did not stain any structures.
Antiserum 934. In the formaldehyde-fixed tissues, the distribution of MEAGLimmunoreactive structures was similar to that revealed by antiserum 935. Carbodiimide-fixed tissue contained substantially fewer MEAGLimmunoreactive fibers than formaldehyde-fixed tissue.
Discussion
Specificity of MEAGL Antisera
Antiserum 935 recognized the glutaraldehyde-induced MEAGL con-jugate against which it was raised, but failed to detect metor leu-enkephalin, MEAP, or FMRFamide conjugates prepared under identical conditions. This suggests strongly that antiserum 935 specifically detects the carboxyl terminus of the MEAGL molecule. This is also supported by pre-absorption experiments in which metor leu-enkephalin conjugates failed to inhibit immunoreactivity of antiserum 935 to the MEAGL conjugate. Therefore, our observations indicate that antiserum 935 is highly specific for MEAGL and can be used to visualize pro-enkephalin A-derived opioid peptides.
In contrast, antiserum 934 recognized not only the carbodiimideinduced MEAGLHC conjugate against which it was raised but also the corresponding met-enkephalin-HC and leu-enkephalin-HC conjugates. Recognition occurred at equal concentration for each conjugate, indicating a high degree of crossreactivity. This suggests that antiserum 934 detects the amino terminus of the MEAGL molecule, which is identical for all three peptides. Antiserum 934 also recognized glutaraldehyde-induced MEAGL conjugate but not glutaraldehyde-induced met-or leu-enkephalin conjugates, showing that some of its antibodies are directed against the MEAGL carboxyl terminus. In conclusion, carbodiimide-induced conjugation may result in variable conjugates that expose different epitopes for immunological recognition. Therefore, corresponding antisera, such as 934, cannot be used for specific demonstration of MEAGL, although they may be usable as general indicators of enkephalins.
Speczycity of Met-enldephalin and FMRFamide Antisera
Met-enkephalin antiserum, which was raised against glutaraldehyde-induced conjugate, readily recognized the glutaraldehyde-induced met-enkephalin conjugate and also the corresponding leu-enkephalin conjugate with the same sensitivity and, to a somewhat lesser extent, the glutaraldehyde-induced MEAGL and MEAP conjugates. It failed to recognize the FMRFamide conjugate. The poor reactivity of the met-enkephalin antiserum for the carbodiimide-induced met-enkephalin conjugate is most probably due to the fact that the antiserum was raised against glutaraldehyde-induced metenkephalin conjugate.
FMRFamide antiserum detected, in addition to FMRFamide conjugate, also MEAP conjugate, but none of the other conjugates. These crossreactivities are in good accordance with the structural relationships between these peptides (Figure 1) .
Glutaraldehyde-induced Conjugation
Use of glutaraldehyde as a coupling agent is based on its bifunc-tional structure: the five-carbon chain contains at each end a highly reactive aldehyde group, so that glutaraldehyde itself becomes a part of the conjugate. Our results suggest that at pH 7.4 glutaraldehyde couples met-and leu-enkephalin and MEAGL to the carrier protein at a site close to the peptide amino terminus, and therefore produces an antigen in which the carboxyl terminus is exposed for antibody production. Considering the amino acid sequences of these peptides (Figure I) , it is likely that the coupling site is either the amino terminus or the tyrosine residue. This view is supported by previous observations that glutaraldehyde reacts primarily with N-terminal amino groups of proteins and peptides (2,3) , and to some extent with the phenolic ring of tyrosine (12). Furthermore, since glutaraldehyde reacts with glycine and phenylalanine only through their free amino groups (12), these residues are unlikely coupling sites. Likewise, coupling through methionine, leucine, or glycine is ruled out, since these do not possess aldehydereactive side groups ( 5 ) . Coupling with the guanidino group of arginine is unlikely since, first, at the pH used this group is completely protonated and, second, such coupling would have resulted in conjugates having afree amino terminus, yet antiserum 935 evidently did not recognize the N-terminus of MEAGL or the pentapeptides.
Conjugation by glutaraldehyde occurs under a wide range of neutral to alkaline pH. This conclusion arises from the finding that antiserum 935 and met-enkephalin antiserum pre-absorbed with the carrier protein readily detected the glutaraldehyde-induced MEAGLHC and met-enkephalin-HC conjugates raised at pH 7.4 and 9.0. Furthermore, since antiserum 935 evidently recognizes the carboxyl terminus but not the amino terminus of MEAGL, our results suggest that rise in pH does not affect specificity of the conjugate. Neither antiserum recognized conjugates raised at pH 5 . 5 . This is probably due to failure of conjugation per se under acidic conditions, rather than to differences in specificity between conjugates raised at neutral-alkaline or acidic pH. This conclusion is based on the finding that not even antiserum 934, which recognizes both the N-and the C-terminus of MEAGL, detected the MEAGL conjugate raised at pH 5.5. Our observations are in good agreement with previous results reporting that binding of glutaraldehyde by protein is strongly dependent on pH: optimal binding with collagen occurs around pH 7-8, and increase in pH is accompanied by increase in binding up to pH 9, while decrease in pH strongly diminishes binding ( 5 ) .
Antisera raised against glutaraldehyde-coupled opioid peptide-protein conjugates have been used in several previous studies. These studies report only 0.1-1% crossreactivity between met-and leu-enkephalin (4,6,21, 26, 39) and no crossreactivity between the pentapeptides the MEAP and MEAGL (25, 31, 42, 43) . Our study is in good agreement with these results and supplements them in demonstrating that the glutaraldehyde coupling method produces antibodies specific for the MEAGL C-terminus.
Carbodiimide-induced Conjugation
The chemical basis for use of carbodiimides as coupling agents is their ability to activate carboxyl groups, making them susceptible to attack by nucleophilic groups which, in the case of an amino group, results in formation of a peptide bond (18,34). Carbodiimide itself does not become part of the conjugate. Our results suggest that carbodiimide-induced conjugation of MEAGL to pro-tein produces a mixture of conjugates, some of which possess a free C-terminus and some a free N-terminus of the MEAGL molecule. pH is not a critical factor for either carbodiimide-induced conjugation per se or specificity of the conjugates.
Conjugates having a free MEAGL C-terminus could be formed in two ways: first, by reaction of the MEAGL a-amino group with an activated carboxyl group of glutaraldehyde-treated hemocyanin (18, 34) or, second, by coupling of.MEAGL tyrosine residue to some nucleophilic group of hemocyanin based on reaction of carbodiimides with the phenolic hydroxyl group (14). On the other hand, conjugates having a free MEAGL N-terminus could result from coupling of an activated MEAGL carboxyl group with the protein. Such coupling would involve a nucleophilic group of the protein other than the amino groups, which can be assumed to be blocked after glutaraldehyde treatment. Given these possibilities, it is conceivable that carbodiimide produces variable conjugates regardless of reaction conditions.
Other studies have reported the use of carbodiimide-coupled opioid peptide conjugates for antiserum production. Crossreactivity between met-and leu-enkephalin reportedly varies from 0.1% to 20% (9, 32, 40, 41) . In contrast with our results, a previously reported antiserum raised against carbodiimide-coupled MEAGL showed no crossreactivity for other opioid peptide conjugates (16). In this as well as in other previous studies, crossreactivity has been assayed using RIA technique in which labeled peptide is first bound by the antiserum tested and displacement by unlabeled peptides is then monitored. Although this method provides a good measure of antiserum specificity when used for detection of actual peptides, it may be biased as a measure of histochemical specificity, since immunohistochemical localization of opioid peptides, and all small molecules, is based on detection of conjugates of the peptides with tissue proteins rather than the native peptide. The immunoblotting technique used in the present study, in contrast to RIA, detects immunoreactivities against peptide-protein conjugates and therefore may provide a more accurate estimate of crossreactivities for histochemical purposes.
Tissue Ftjuztion
In the previous studies on enkephalin immunohistochemistry, formaldehyde alone has been used as the fixative regardless of whether carbodiimide or glutaraldehyde was used in the preparation of the antiserum (10,13,16,31) . The present study demonstrates that addition of glutaraldehyde to the fmtive enhances immunoreactivity for glutaraldehyde-induced MEAGLprotein conjugate. Corresponding enhancement of immunoreactivity by glutaraldehyde supplement in the fixative has been reported previously for GABA (33) . In tissues such as the spinal cord and the pituitary gland, glutaraldehyde addition revealed structures that were not shown after mere formaldehyde fmtion. In autonomic ganglia, no new structures were revealed after glutaraldehyde addition, and therefore possible enhancement is difficult to detect by qualitative estimation.
Lack of enhancement after carbodiimide fixation in immunoreactivity for carbodbide-induced MEAGLprotein conjugate is unexpected, since other small molecules, such as histamine and glucagon, have been successfully coupled to protein with carbodiimide and visualized immunohistochemically in carbodiimide-fmed tissue, whereas attempts to visualize these substances in formaldehyde-fsed tissue have succeeded poorly or not at all (17,29; and Panula, personal communication). Since both ends of the MEAGL molecule can be involved in reactions with carbodiimide, failure of carbodiimide fixation to enhance MEAGL immunoreactivity may be due to formation of MEAGL polymers in tissue having antigenic epitopes different from those of the original conjugate.
MEAGL Innervation of the Pituitary Gland
Our finding on the dense MEAGLimmunoreactive innervation in the pituitary intermediate lobe fulfilled the immunohistochemical specificity criteria. Glutaraldehyde-induced artifactual epitopes formed during fixation are an unlikely explanation of the observed staining, since the antiserum raised against glutaraldehyde-treated carrier protein did not stain any structures. Although the result must await chemical confirmation by non-immunological methods, it tentatively offers a reinterpretation of opioid regulation of the intermediate lobe. Studies performed on isolated glands indicate inhibition of a-MSH secretion by leu-enkephalin (1) . Since no enkephalin-containing nerves have been described in the intermediate lobe, this inhibition has been considered as an effect of circulating opioid peptides. The present results speak for direct neural control by pro-enkephalin A-derived peptide(s) at the level of the intermediate lobe. In support of this view, MEAGL-immunoreactive neurons have been described in the arcuate nucleus and dorsomedial nucleus of the hypothalamus, as well as in the dorsal raphe nucleus (10,20), all of which are known to project into the intermediate lobe.
General Implications of the Present Findings
Our results indicate that glutaraldehyde can be used as a coupling agent to selectively conjugate the amino terminus of MEAGL to a carrier protein and to produce antiserum specific for the carboxyl terminus. Use of carbodiimide is more complicated owing to multiple reactions, and selective coupling would require application of protective agents. The utility of glutaraldehyde is derived from its properties per se, and from those of peptides and proteins in general, rather than from properties specific for MEAGL. Therefore, the principles involved in these reactions should be applicable to other peptide-protein conjugation reactions as well. This should be particularly useful when selective coupling is desired in order to differentiate the immunoreactivity of closely related members of peptide families.
